A robust clinical trial ecosystem is fundamental to the growth of the India Antibodies Market. India offers a diverse patient population and a large network of clinical research organizations (CROs) capable of executing complex trials for antibody-based products. This environment allows companies to gather necessary data on efficacy and safety, which is a prerequisite for both local and...